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Abstract
Background: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is
debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians
would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a
clinical trial and their current practice in managing adults admitted to hospital with suspected influenza.
Methods: Senior clinicians (n = 50) across the UK actively involved in the care of patients hospitalised with severe
respiratory infections and/or respiratory infection research were invited to participate in an on-line survey.
Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in
relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is
virolologically confirmed, prescribing NAIs.
Results: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious
diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at
reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults
admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated
they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat
empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients
presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%)
clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU
wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%)
would participate in such a trial.
Conclusions: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults
hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates
collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of
treatment would not substantially divert patients towards placebo.
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Background
Influenza viruses circulate constantly across the globe,
typically causing annual epidemics in temperate regions
during the winter months. [1] Annual influenza vaccin-
ation is available, which provides some protection
against the virus. For the majority of individuals who
contract influenza, symptoms are short lived and self-
limiting. However, influenza illness can also be severe,
particularly among certain susceptible groups such as
adults over the age of 65 and individuals with comorbid-
ities. [2] Individuals in these groups are more likely to
require hospital admission due to influenza infection
and influenza complications may lead to death. [3, 4] In
the UK, seasonal influenza is associated with an average
of approximately 8000 attributable deaths per year. [5]
Neuraminidase inhibitors (NAIs) such as oseltamivir
and zanamivir are licenced and available for the treat-
ment of influenza infection. Based on evidence gener-
ated from randomised controlled trials (RCTs) and
subsequent meta-analyses, there is general consensus
that NAI treatment in uncomplicated seasonal influ-
enza is associated with a reduction in symptom dur-
ation of influenza illness by several hours. [6, 7]
However, interpretation of the mechanism of this ef-
fect differs; the Cochrane group suggested that oselta-
mivir had no specific antiviral effect, while the
Roche-funded review group found that benefit with
oseltamivir was limited to the intention-to-treat-in-
fected (influenza confirmed) group suggesting a spe-
cific effect on the influenza virus. [6, 7]
Debate regarding the effectiveness of NAIs in reducing
severe outcomes amongst patients hospitalised with in-
fluenza is even more intense, reflecting the incomplete
evidence base in relation to complicated, or severe, influ-
enza. No relevant placebo-controlled RCTs are available
to directly inform the debate, instead, the strongest evi-
dence is derived from large observational cohorts, domi-
nated by studies of the use of NAIs for the treatment of
pandemic influenza A(H1N1)pdm09. [6–8] An individ-
ual participant data (IPD) meta-analysis of data from 78
different observational studies, which included > 29,000
patients, found that the odds of death for adults treated
with NAIs within 48 h of symptoms onset, compared to
untreated adults was 0.50 (95% CI 0.37–0.67). [9]
Although a range of biases were adjusted for within the
meta-analysis, further biases may have remained un-
accounted for. In reviewing the evidence for NAI use in
influenza, an independent steering group of the Academy
of Medical Sciences, supported by the Wellcome Trust,
acknowledged that although observational studies are
generally at higher risk of bias than RCTs, that did not
necessarily invalidate the evidence generated by such
studies. [10] The report supports the use of NAIs for the
treatment of patients hospitalised with influenza, whilst at
the same time recognising that the strength of evidence
surrounding the effectiveness of NAIs in reducing influ-
enza mortality is sub-optimal and recommending that, in
order to improve the evidence base, a RCT investigating
the effectiveness of NAI treatment in reducing influenza
mortality should be a research priority.
In the UK, NICE Guideline TA 168 (2009) recom-
mends the use of NAIs in ‘at-risk’ persons who present
with an influenza-like illness (when influenza is circulat-
ing in the community) and who can start treatment
within 48 h of the onset of symptoms (or within 36 h for
zanamivir treatment in children). [11] Public Health
England guidance goes further and recommends that all
patients hospitalised with influenza should receive treat-
ment with NAIs; treatment should be started as early as
possible without waiting for laboratory confirmation of
influenza virus infection. [12] Notably within this recom-
mendation, timing from symptom onset to initiation of
NAI is not limited to within 48 h of symptom onset.
Given these, and similar guidelines in other countries,
there is a view that a RCT involving patients hospitalised
with influenza “could not ethically evaluate active treatment
versus placebo treatment”. [8] However, in UK clinical
practice, adherence to these guidelines is low and
NAIs are used infrequently, both in primary care and
in hospital settings. This mismatch between clinical
practice and guideline recommendation has important
implications for clinical care and the feasibility of the
conduct of a definitive RCT of NAI treatment in
hospitalised patients.
We conducted a nation-wide survey of senior hos-
pital clinicians in the fields of respiratory medicine,
intensive care medicine and infectious diseases, who
are active in research and clinical care of patients
with influenza, to gain some insight into their current
practice for managing patients with suspected and
confirmed influenza, and their opinion on the necessity
for a RCT.
Methods
An online survey of United Kingdom (UK) clinicians
was conducted from 23 February 2017 to 15 March
2017. Clinicians actively involved in the care of patients
hospitalised with severe respiratory infections and/or re-
spiratory infection research were approached, including
investigators (n = 36) involved in the National Institute
for Health Research (NIHR) funded pandemic influenza
Adjuvant Steroids in Adults with Pandemic Influenza
(ASAP) trial. [13] Clinicians not involved in the ASAP
trial were selected based on their recognition as opinion-
leaders in relation to the management of respiratory tract
infections, nationally or within their institutions; all
clinicians approached were of Consultant grade.
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Fifty clinicians were approached via email containing
information about the proposed trial and asking them to
complete the survey. The email contained a direct link
to the survey which consisted of six multiple-choice
questions asking about their current belief in the
strength of the evidence surrounding NAI efficacy, their
current practice in testing and treating patients hospita-
lised with suspected or confirmed influenza and if they
think that there is the need for a RCT to be conducted
(see Additional file 1 Appendix A for survey questions).
A follow up email containing the survey information
was sent to those who had not responded after the
first week.
Statistical analyses
Results were analysed using R. [14] Descriptive statistics
were used to analyse the proportions of respondents and
Fisher’s exact test was used to calculate p values. A p
value of < 0.05 was considered statistically significant.
Results
Perceived evidence and need for a trial
There was a good response rate with 35 (70%) of 50 cli-
nicians completing the survey. Intensive Care Medicine
specialists and Respiratory Medicine specialists each
comprised approximately one third of the respondents
(Table 1).
When asked about their stance regarding the current
evidence surrounding NAI effectiveness, 26 (74%) agreed
that NAIs were effective at reducing influenza symptom
duration, while 6 (17%) neither agreed nor disagreed.
But only 11 (31%) agreed that NAIs were effective at
reducing influenza mortality while 14 (40%) disagreed,
feeling that NAIs are not effective (or unproven) at redu-
cing influenza mortality (Fig. 1).
Thirty-one (89%) clinicians agreed that ‘a randomised
placebo-controlled trial to determine the clinical benefit
and cost-effectiveness of neuraminidase inhibitors in
adults admitted to hospital with suspected influenza
infection should be conducted in the UK’ and 29 (85%)
clinicians indicated interest in participating in such a trial.
Testing for influenza in adults hospitalized during the
influenza season
Clinicians were asked about their current practice sur-
rounding the testing and treatment of adults admitted to
hospital during the influenza season with: a) pneumonia;
b) an exacerbation of chronic lung disease; c) non-
pneumonic lower respiratory tract infection (LRTI); and
d) other diagnoses. For adults admitted to non-ICU
wards, 10 (34.5%) clinicians indicated that they would
test for influenza in greater than 60% of patients with
pneumonia, and 15 (51.7%) clinicians in total would test
greater than 60% of patients admitted with any respira-
tory infection (pneumonia, exacerbation of chronic lung
disease or LRTI combined) (Fig. 2). Corresponding fig-
ures for adults admitted to ICU were higher; 25 (80.6%)
clinicians would test greater than 60% patients with
pneumonia (p = 0.0003), and 28 (90.3%) clinicians would
test greater than 60% of patients admitted with any
respiratory infection (p = 0.001). Few clinicians would
test greater than 60% of adults presenting with other
diagnoses, whether admitted to non-ICU wards (n = 3
(10.3%) or ICU (n = 6 (20.7%)).
Empirical use of NAIs in adults hospitalized during the
influenza season
A wide range in the empirical use of NAIs (i.e. when no
influenza test result is available) for the treatment of
adults admitted with respiratory tract infections was
reported. For adults admitted to non-ICU wards, only 5
(17.2%) clinicians would treat empirically with NAIs in
greater than 60% of patients with pneumonia and, only 9
(31.0%) clinicians in total would prescribe NAIs empiric-
ally to greater than 60% of patients admitted with any
respiratory infection. Corresponding figures were higher
for adults admitted to ICU; 12 (38.7%) clinicians would
treat empirically with NAIs in greater than 60% of
patients with pneumonia (p = 0.09) and 16 (51.6%)
clinicians would treat empirically with NAIs in greater
than 60% of patients with any respiratory tract infection
(p = 0.12) (Fig. 3).
Use of NAIs when influenza infection is confirmed
Most, but not all, clinicians reported that they would
prescribe NAIs to greater than 80% of hospitalised
adults when influenza infection is confirmed by an influ-
enza test (Fig. 4). Specifically, for adults admitted to
non-ICU wards, 16 (61.5%) clinicians would prescribe
NAIs in greater than 80% of patients with pneumonia,
and 17 (65.4%) clinicians in total would prescribe NAIs
in greater than 80% of patients admitted with any
respiratory infection.
With regard to adults presenting with illnesses other
than a respiratory tract infection in whom influenza
infection is confirmed, 11 (42.3%) clinicians would prescribe
Table 1 Survey respondents’ medical specialties (n = 35)
Specialty n (%)
Intensive Care Medicine 12 (34.3)
Respiratory Medicine 11 (31.4)
Infectious Diseases 6 (17.1)
Acute Medicine 3 (8.6)
Emergency Medicine 3 (8.6)
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NAIs in greater than 80% of such patients admitted to non-
ICU wards compared to 16 (57.1%) clinicians for such pa-
tients admitted to ICU.
Discussion
The key finding of this survey was the wide range of
opinions held by clinicians regarding the effectiveness of
NAIs in reducing mortality in patients with influenza; a
third of clinicians agreed that NAIs are effective at
reducing influenza mortality, a third disagreed and a
third neither agreed nor disagreed. This finding carried
through to reported clinical practice, with significant
variation amongst UK clinicians in relation to the use of
NAIs for the treatment of adults hospitalised with sus-
pected influenza infection.
Despite existing PHE guidance recommending a ‘treat
and test’ approach to patients admitted to hospital with
suspected influenza, the majority of clinicians reported
that they would not offer empirical NAI treatment, nor
test for influenza infection in most patients regardless of
presenting symptoms. Indeed, in patients presenting
with pneumonia, in whom it might be expected that
empirical NAI treatment would be highest, only 10% of
clinicians would offer empirical NAI treatment, and only
35% would test for influenza, in over 60% of ward-based
patients. Even when influenza infection is confirmed,
only 62% of clinicians would prescribe NAIs in greater
than 80% of ward-based patients. A similar trend of very
low compliance with PHE guidance was apparent for
ward-based patients presenting with less severe respira-
tory tract infections.
These findings suggest that a placebo-controlled RCT with
a 1:1 individual randomisation approach would not lead to
an overall diversion of patients from receiving NAI treatment
to receiving placebo treatment. Instead, compared with
current care, conduct of a RCT would likely lead to more
patients with suspected influenza being offered empirical
treatment with NAIs and more patients being tested for in-
fluenza infection, in accordance with PHE guidance.
For critically ill patients, reported empirical treatment
with NAIs was still lower than might be expected with
only 38% of clinicians indicating they would empirically
treat over 60% of patients presenting with pneumonia.
However, the propensity to test for influenza was much
Fig. 1 How strongly do you agree or disagree with the following statements about the current evidence for the use of neuraminidase inhibitors
(e.g. oseltamivir, zanamivir) in adults hospitalised with suspected influenza?
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higher in critical care; 81% of clinicians would test over
60% of patients with pneumonia.
When confronted by a patient with confirmed influ-
enza infection, the vast majority of clinicians would
prescribe NAI treatment for critically ill patients. For
ward-based patients, a smaller majority would prescribe
NAI treatment; reasons for this difference in opinion
were not explored within the survey. Clinicians who are
not convinced that NAI treatment provides a survival
advantage may feel that confirmation of influenza infec-
tion alone does not always justify immediate NAI treat-
ment, but would take into account other factors such
time from symptom onset, initial clinical response to
supportive treatment, the likelihood of bacterial co-
infection, and patient-related prognostic factors. As the
odds of death increase, such as in critically ill patients,
clinicians may feel more obliged or compelled to offer
NAI treatment, despite doubts regarding the beneficial
effects of NAIs. Of course, issues regarding whether or
not to treat confirmed influenza infection only arise if
testing for influenza occurs in the first place.
Strengths and weaknesses
Although this survey was relatively small, it had a
good response rate of 70%, was nation-wide and was
representative of a good range of medical specialties.
Respondents were senior, experienced clinicians with
an interest in influenza and respiratory tract infec-
tions who would be expected to be familiar with the
existing evidence base. Many respondents were also
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Fig. 2 How often do you test for influenza in each of the following groups of adults hospitalised during the influenza season?Legend: PNA – pneumonia,
CLD - Exacerbation of chronic lung disease (e.g. COPD, asthma), LRTI – non-pneumonic lower respiratory tract infection, Other – other acute medical
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active researchers in and around the field of influ-
enza. Therefore, the results of the survey represent
the views of well-informed and motivated clinicians
and clinical academics. We have no reason to expect
that clinicians with less interest or expertise in influ-
enza (who are under-represented in this survey)
would express markedly different viewpoints.
In a minority of UK hospitals currently, point-of-care
influenza testing is available. This may have influenced
the responses given by clinicians in relation to both test-
ing for influenza infection and the empirical treatment
with NAIs. However, this is likely to be relevant to only
a very small proportion of clinicians who responded to
the survey and is unlikely to materially alter overall con-
clusions of the survey. Likewise, some choices in clinical
practice, such as testing for influenza, may be influenced
by policy within the clinician’s hospital.
Research implications of findings
From an ethical viewpoint, a clinical trial is generally
considered to be justified when there exists ‘an honest,
professional disagreement among expert clinicians about
the preferred treatment’. [15] If experts are equally
divided over the issue, ‘clinical equipoise’ or ‘collective
equipoise’ is said to exist and “when deciding if a trial is
ethically justified, collective equipoise is considered more
important than the individual preferences of attending cli-
nicians”. [16] This survey suggests that in UK clinical prac-
tice, notwithstanding existing public health guidance on
NAI use, there is indeed clinical and collective equipoise as
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Fig. 3 How often do you prescribe neuraminidase inhibitors empirically (i.e. before any influenza test result becomes available) in the following
groups of adults hospitalised during the influenza season?Legend: PNA – pneumonia, CLD - Exacerbation of chronic lung disease (e.g. COPD,
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regards the use of NAIs for adults hospitalised with severe
influenza.
In situations where the chances of dying are very high
and there is no apparent effective intervention (apart
from the trial intervention), it may sometimes be main-
tained that clinical equipoise alone is not sufficient to
justify imposing a randomised clinical trial upon clinical
practice; as was argued during the 2014 Ebola outbreak
in Africa. [17, 18] Whilst very high mortality rates might
pertain in a severe influenza pandemic, in the case of
seasonal influenza, mortality rates in hospitalised pa-
tients managed according to usual standard of care
(SOC) in the UK (which for the most part does not
include NAI treatment) ranges between 4 to 23%;
similar to mortality rates for community acquired
pneumonia. [2, 19] Thus, SOC cannot be considered
to be ineffectual in severe seasonal influenza infec-
tion, and predictions of high mortality in any individ-
ual circumstance are fallible.
The findings from this survey provide a valuable counter-
point to the view that a placebo-controlled RCT of NAI use
in adults hospitalised with influenza cannot be conducted on
ethical grounds. Instead, there was overwhelming agreement
(89%) amongst survey respondents in support of a placebo-
controlled RCT trial and given the low current use of NAIs
in untested patients, randomisation would not substantially
divert patients who would normally be treated with NAIs
towards placebo. An adaptive trial design that includes pre-
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Fig. 4 How often do you prescribe neuraminidase inhibitors in each of the following groups of hospitalised adults when influenza infection is
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determined interim analyses will enable a large treatment
effect (should one exist), such as a 50% reduction in mortal-
ity as suggested by the PRIDE IPD meta-analysis, to be
detected with good confidence at an earlier stage in the trial.
[9] This would mitigate against concerns about unnecessarily
exposing large numbers of patients to inferior treatment
options. [20] In addition, an adaptive trial design would allow
emerging antiviral treatments, including non-NAI antiviral
agents, or adjuvant therapies to be tested in a robust and
systematic manner. [13, 21]
The downgrading of oseltamivir from the World Health
Organization (WHO) list of essential medicines from
‘core’ to ‘complementary’ in September 2017 has fuelled
further debate regarding the value of NAI treatment in
severe influenza. [22] Such debate is important in raising
public awareness regarding the uncertainties in the
evidence base as it currently stands. As public perception
changes, patient expectations are likely to alter as well. In
addition to the clinician survey, we also organised two
Patient and Public Involvement (PPI) meetings to discuss
the acceptability of a RCT of NAI treatment in hospita-
lised patients with influenza. At these meetings, PPI mem-
bers placed a high value on the results from the survey in
informing their own views.
Further work is warranted to broaden the consultation
to include clinicians based outside of the UK or working
within different medical specialties. As this was a self-
reported survey, it is possible that clinician responses
may differ from their actual practice; measuring actual
practice in a hospital setting would improve the strength
of these findings.
Conclusions
UK clinicians strongly support a placebo-controlled RCT
of NAI treatment in adults hospitalised with suspected
influenza. Current variation in medical opinion and
clinical practice is not a sustainable platform for providing
patients with suspected influenza the best standard of care
possible.
Additional file
Additional file 1: Appendix – Survey Questions, Survey Questions,
Survey questions sent to clinicians. (PDF 56 kb)
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